Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has announced a deal to acquire Proteologix, a US-based specialist in immune-mediated diseases, for a base purchase price of USD 850 million with additional potential milestone payments. The transaction is anticipated to be finalized by mid-2024.
Proteologix is known for its focus on bispecific antibodies (BsAbs), with key candidates PX128 and PX130 at the forefront of its pipeline. PX128 targets IL-13 and TSLP and is poised to advance into clinical development for the treatment of moderate-to-severe atopic dermatitis (AD) and moderate-to-severe asthma. The other lead asset, PX130, is designed to address moderate-to-severe AD, focusing on a distinct pathway by targeting IL-13 and IL-22.- Flcube.com
